Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kα inhibitor (IC50 = 0.038 nM). It binds to the ATP-binding site of PI3Kα, inhibiting PIP2 phosphorylation to PIP3. Inavolisib exhibits greater selectivity for mutant PI3Kα over the wild-type and is used in breast cancer research. Reagent grade, for research use only.
Usually ships within 24 hours.